Monday may have been a holiday, but New England’s tech and life sciences companies haven’t slowed down their deal making. We’ve had plenty of headlines of acquisitions, an IPO, and venture funding rounds for companies we’ve covered before and other not-so-familiar names.
—Expressor Software, a Burlington, MA-based integration software provider, raised $4.5 million in expansion capital funding. The money comes from existing Expressor investors Commonwealth Capital Ventures, Globespan Capital Partners, and Sigma Partners.
—Waltham, MA-based Xkoto, a maker of database virtualization software for businesses, confirmed that it had been acquired by business intelligence giant Teradata (NYSE: [[ticker:TDC]]). Xkoto, which raised a $3 million Series C round last year from GrandBanks Capital and GrowthWorks Canadian Fund, said the companies don’t plan to disclose the financial terms of the acquisition.
—OzVision Global, a maker of remote video platforms for surveillance and telecommunications companies, raised $4.9 million of a planned $6.7 million offering of debt that can be converted into equity. The Woburn, MA-based company is backed by Aviv Venture Capital and Kardan Communications.
—Tesaro, a new Boston biotech company that plans to develop and acquire cancer drugs and other oncology products, said it has pulled in $20 million in a Series A financing. The money comes from the company’s founders and New Enterprise Associates, which has reserved another $40 million to support Tesaro over time.
—Waltham-based drug developer Logical Therapeutics announced it had wrapped up a $16.9 million Series C financing, led by SV Life Sciences. Burrill & Co., Novo A/S, and Novitas Capital participated in the round, which we first covered when an SEC filing showed that the company pulled in $10 million.
—Thermo Fisher Scientific said it will acquire Fermentas International, a Canadian maker of life sciences research materials and diagnostic tools, for $260 million in cash. Waltham-based Thermo said it expects to
